Zhejiang Heze Pharmaceutical Technology Co., Ltd. is involved in pharmaceutical research and development. The company specializes in generic drug development, consistency evaluation of generic drugs, pharmaceutical research, innovative drug development, and clinical trial services. Established on October 27, 2006, it is headquartered in Hangzhou, China.

Tags

Endocrinology and Metabolic Disease

Nervous System Diseases

Digestive System Disorders

Small molecule drug

Chemical drugs

Synthetic peptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	3
Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	4
Chemical drugs	2
Synthetic peptide	2

Top 5 Target	Count

GIPR x GLP-1R	2
CYP17A1(Steroid 17-alpha-hydroxylase)	1
GLP-1R(Glucagon-like peptide 1 receptor)	1
5-HT1A receptor x 5-HT2A receptor x D2 receptor	1
PLG(Plasminogen)	1

Drugs associated with Zhejiang Heze Pharmaceutical Technology Co., Ltd.

Brexpiprazole

Target

5-HT1A receptor x 5-HT2A receptor x D2 receptor

Mechanism

5-HT1A receptor agonists [+2]

Active Org.

Otsuka Pharmaceutical Co., Ltd. [+23]

Originator Org.

Otsuka Pharmaceutical Co., Ltd.

Active Indication

Depressive Disorder [+10]

Inactive Indication

Anxiety Disorders [+11]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date10 Jul 2015

Abiraterone acetate

Target

CYP17A1

Mechanism

CYP17A1 inhibitors

Active Org.

Accord Healthcare SLU [+17]

Originator Org.

Johnson & Johnson

Active Indication

Prostate Neuroendocrine Carcinoma [+9]

Inactive Indication

Adenocarcinoma [+9]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date28 Apr 2011

Ambroxol Hydrochloride

Target

SCNA

Mechanism

SCNA modulators

Active Org.

Shanxi Yanghe Pharmaceutical Technology Co., Ltd. [+32]

Originator Org.

Teijin Pharma Ltd.

Active Indication

Chronic sinusitis [+22]

Inactive Indication

Acute pharyngitis [+1]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date27 May 1983

Clinical Trials associated with Zhejiang Heze Pharmaceutical Technology Co., Ltd.

CTR20244084

/ RecruitingPhase 3

一项随机、双盲双模拟、平行对照、多中心临床研究，评价缬沙坦左氨氯地平片治疗轻至中度原发性高血压的有效性和安全性

[Translation] A randomized, double-blind, double-dummy, parallel-controlled, multicenter clinical study to evaluate the efficacy and safety of valsartan-amlodipine tablets in the treatment of mild to moderate essential hypertension

1) 评价缬沙坦左氨氯地平片（规格：80mg/2.5mg）治疗轻至中度原发性高血压的有效性； 2) 评价缬沙坦左氨氯地平片（规格：80mg/2.5mg）治疗轻至中度原发性高血压的安全性。

[Translation]

1) To evaluate the effectiveness of valsartan levamlodipine tablets (specification: 80mg/2.5mg) in the treatment of mild to moderate essential hypertension; 2) To evaluate the safety of valsartan levamlodipine tablets (specification: 80mg/2.5mg) in the treatment of mild to moderate essential hypertension.

Start Date19 Dec 2024

Sponsor / Collaborator

Zhejiang Hemukang Pharmaceutical Technology Co., Ltd.

CTR20243359

/ RecruitingNot Applicable

健康受试者餐后单次口服缬沙坦左氨氯地平片与缬沙坦片（DIOVAN®）和苯磺酸氨氯地平片（络活喜®）的随机、开放、三序列、三周期、部分重复交叉设计的生物等效性试验

[Translation] A randomized, open-label, three-sequence, three-period, partially repeated crossover bioequivalence study of a single oral dose of valsartan-levoamlodipine tablets compared with valsartan tablets (DIOVAN®) and amlodipine besylate tablets (Norvasc®) in healthy volunteers

研究餐后状态下单次口服受试制剂缬沙坦左氨氯地平片（规格：80 mg/2.5 mg）与参比制剂缬沙坦片（DIOVAN®，规格：80 mg）、苯磺酸氨氯地平片（络活喜®，规格：5 mg）在中国健康人体的相对生物利用度，分析两种制剂的药代动力学参数，评估餐后状态口服两种制剂的生物等效性，为该药的申报及临床用药提供参考依据。

[Translation]

The relative bioavailability of a single oral dose of the test preparation valsartan levoamlodipine tablets (specification: 80 mg/2.5 mg) and the reference preparations valsartan tablets (DIOVAN®, specification: 80 mg) and amlodipine besylate tablets (Norvasc®, specification: 5 mg) in healthy Chinese volunteers was studied. The pharmacokinetic parameters of the two preparations were analyzed and the bioequivalence of the two preparations after oral administration in the fed state was evaluated, so as to provide a reference for the application and clinical use of the drug.

Start Date14 Dec 2024

Sponsor / Collaborator

Zhejiang Hemukang Pharmaceutical Technology Co., Ltd.

CTR20243538

/ CompletedNot Applicable

比拉斯汀口腔崩解片（10 mg）在中国健康受试者中随机、开放、两制剂、两周期、双交叉空腹状态下生物等效性试验

[Translation] A randomized, open-label, two-dose, two-period, double-crossover bioequivalence study of bilastine orally disintegrating tablets (10 mg) in Chinese healthy subjects under fasting conditions

研究空腹状态下单次口服受试制剂（T）比拉斯汀口腔崩解片（规格：10mg；江苏和晨药业有限公司生产及提供）与参比制剂（R）比拉斯汀口腔崩解片（Bilaxten®，规格：10mg；Menarini International Operations Luxembourg S.A.持证；江苏和晨药业有限公司提供）在健康成年受试者体内的药代动力学行为，评价空腹口服两种制剂的生物等效性。

[Translation]

The pharmacokinetic behavior of the test formulation (T) bilastine orally disintegrating tablets (specification: 10 mg; produced and provided by Jiangsu Hechen Pharmaceutical Co., Ltd.) and the reference formulation (R) bilastine orally disintegrating tablets (Bilaxten®, specification: 10 mg; licensed by Menarini International Operations Luxembourg S.A.; provided by Jiangsu Hechen Pharmaceutical Co., Ltd.) after a single oral dose in healthy adult subjects under fasting conditions was studied, and the bioequivalence of the two formulations after oral administration under fasting conditions was evaluated.

Start Date13 Oct 2024

Sponsor / Collaborator

Jiangsu Hechen Pharmaceutical Co., Ltd.

100 Clinical Results associated with Zhejiang Heze Pharmaceutical Technology Co., Ltd.

0 Patents (Medical) associated with Zhejiang Heze Pharmaceutical Technology Co., Ltd.

Literatures (Medical) associated with Zhejiang Heze Pharmaceutical Technology Co., Ltd.

Lihua Jianyan, Huaxue Fence

Determination of levoisomer in (R) -lansoprazole for injection by normal phase high performance liquid chromatography

Author: Zhang, Lihua ; Pan, Zhengmao ; Mao, Chunxin

The (R) -lansoprazole powder for injection was dissolved in methanol to prepare a 5.00 mg·L^-1 sample solution, and chromatog. anal. was carried out under the following conditions: Chiralpak ID chiral column (4.6 mm×250 mm, 5μm) was used as stationary phase, the column temperature was 35 °C, the mobile phase was a mixture of n-hexane, isopropanol and glacial acetic acid (70+30+0.2), the flow rate was 0.6 mL·min^-1, and the diode array detector was used for detection at the wavelength of 285 nm.The results showed that, linear relationship was found between peak area and mass concentration of (S) -lansoprazole in the range of 0.48-4.81 mg·L^-1, the detection limit (3 S/N) was 2.4×10^-3 mg·L^-1, and the lower limit of determination (10 S/N) was 4.8×10^-3 mg·L^-1.Values of recovery obtained by standard addition method were in the range of 97.5%-103%, and RSDs (n=6) were less than 1.6%.

Diabetes, Metabolic Syndrome and Obesity

DR10627, a Novel Dual Glucagon‑like Peptide‑1 and Gastric Inhibitory Polypeptide Receptor Agonist for the Treatment of Obesity and Type 2 Diabetes Mellitus

Article

Author: Fang, Chen ; Chen, Yonglu ; Huang, Jing ; Fu, Weiling ; Sheng, Shimei ; Huang, Yanshan ; Zhu, Mingyue ; Shao, Yujian ; Sun, Peng ; Wang, Minjun ; Liu, Yuanyuan

IntroductionDiabetes and obesity are momentous risk factors threatening people's lives and health. Currently available incretin analogue glucagon-like peptide 1 (GLP-1) possesses huge hypoglycemic effect with the unsatisfactory effect of weight loss. Co-agonists targeting GLP-1R plus glucagon receptor (GCGR) or gastric inhibitory polypeptide receptor (GIPR) show synergistic benefits in glycaemic control and weight loss. Here, we describe a novel dual GIP and GLP-1 receptor agonist, DR10627, and performed a preclinical assessment of it.MethodsThe agonistic ability of DR10627 was indirectly assessed by inducing cAMP accumulation in Chinese hamster ovary (CHO) cells transfected with GLP-1R or GIPR in vitro. The plasma pharmacokinetics of DR10627 were analysed in cynomolgus monkeys. The OGTTs were performed in Sprague‑Dawley (SD) rats. The glucose lowering effects were evaluated by repeated administration of DR10627 in diabetic (db/db) mice for 4 weeks. The effects of anti-obesity and improving metabolism of DR10627 were evaluated by repeated administration of DR10627 in diet-induced obesity (DIO) mice for 57 days.ResultsDR10627 had the capacity to activate both GLP-1R and GIPR in vitro. The terminal half-life of DR10627 was found to be approximately 4.19-5.8 h in cynomolgus monkeys. DR10627 had a great improvement in oral glucose tolerance in SD rats. Moreover, DR10627 had a potent glucose-lowering effect in db/db mice, and the hypoglycemic effect of 18 nmol/kg DR10627 was better than that of 50 nmol/kg liraglutide. In addition, 10 and 30 nmol/kg DR10627 possessed the ability of potentiating the weight-loss, lipid-lowing efficacy and improving metabolism to a greater extent than 80 nmol/kg liraglutide.ConclusionPreclinical assessment demonstrated that administration of DR10627 resulted in glucose lowering in SD rats and db/db mice, and substantial body weight reduction and metabolism improvement in DIO mice. DR10627 is a promising agent deserving further investigation for the treatment of type 2 diabetes and obesity.

PLOS ONEQ3 · CROSS-FIELD

Metabolic networks of plasma and joint fluid base on differential correlation

Q3 · CROSS-FIELD

ArticleOA

Author: Xu, Bingyong ; Zhang, Weidong ; Su, Hong ; Wang, Yixiao ; Wang, Ruya

Whether osteoarthritis (OA) is a systemic metabolic disorder remains controversial. The aim of this study was to investigate the metabolic characteristics between plasma and knee joint fluid (JF) of patients with advanced OA using a differential correlation metabolic (DCM) networks approach. Plasma and JF were collected during the joint replacement surgery of patients with knee OA. The biological samples were pretreated with standard procedures for metabolite analysis. The metabolic profiling was conducted by means of liquid mass spectrometry coupled with a AbsoluteIDQ kit. A DCM network approach was adopted for analyzing the metabolomics data between the plasma and JF. The variation in the correlation of the pairwise metabolites was quantified across the plasma and JF samples, and networks analysis was used to characterize the difference in the correlations of the metabolites from the two sample types. Core metabolites that played an important role in the DCM networks were identified via topological analysis. One hundred advanced OA patients (50 men and 50 women) were included in this study, with an average age of 65.0 ± 7.6 years (65.6 ± 7.1 years for females and 64.4 ± 8.1 years for males) and a mean BMI of 32.6 ± 5.8 kg/m2 (33.4 ± 6.3 kg/m2 for females and 31.7 ± 5.3 kg/m2 for males). Age and BMI matched between the male and female groups. One hundred and forty-five nodes, 567 edges, and 131 nodes, 407 edges were found in the DCM networks (p < 0.05) of the female and male groups, respectively. Six metabolites in the female group and 5 metabolites in the male group were identified as key nodes in the network. There was a significant difference in the differential correlation metabolism networks of plasma and JF that may be related to local joint metabolism. Focusing on these key metabolites may help uncover the pathogenesis of knee OA. In addition, the differential metabolic correlation between plasma and JF mostly overlapped, indicating that these common correlations of pairwise metabolites may be a reflection of systemic characteristics of JF and that most significant correlation variations were just a result of "housekeeping” biological reactions.

100 Deals associated with Zhejiang Heze Pharmaceutical Technology Co., Ltd.

100 Translational Medicine associated with Zhejiang Heze Pharmaceutical Technology Co., Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 28 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

IND Approval

Phase 1 Clinical

Phase 2 Clinical

Phase 3 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Valsartan/Levamlodipine ( PLG )	Essential Hypertension More	Phase 3
Abiraterone acetate ( CYP17A1 )	Hormone-dependent prostate cancer More	Phase 2
HZ-010 ( GIPR x GLP-1R )	Diabetes Mellitus, Type 2 More	Phase 1
HZ-012 ( GIPR x GLP-1R )	Obesity More	Phase 1
Brexpiprazole ( 5-HT1A receptor x 5-HT2A receptor x D2 receptor )	Schizophrenia More	Clinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis